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Abstract
Introduction Metaplastic breast carcinomas constitute a
heterogeneous group of neoplasms, accounting for less than
1% of all invasive mammary carcinomas. Approximately 70–
80% of metaplastic breast carcinomas overexpress the
epidermal growth factor receptor (EGFR). Human epidermal
growth factor receptor (HER)2 and EGFR have attracted much
attention in the medical literature over the past few years owing
to the fact that humanized monoclonal antibodies against HER2
and therapies directed against the extracellular ligand-binding
domain or the intracellular tyrosine kinase domain of EGFR have
proven successful in treating certain types of human cancer. We
investigated whether HER2 and EGFR overexpression was
present and evaluated gene amplification in a series of
metaplastic breast carcinomas.
Method Twenty-five metaplastic breast carcinomas were
immunohistochemically analyzed using a monoclonal antibody
(31G7) for EGFR and two antibodies for HER2 (Herceptest and
CB11) and scored using the Herceptest scoring system. Gene
amplification was evaluated by chromogenic in situ hybridization
using Zymed Spot-Light EGFR and HER2 amplification probe.
The results were evaluated by bright field microscopy under
40× and 63× objective lenses.
Results Nineteen (76%) metaplastic breast carcinomas
exhibited EGFR ovexpression, and among these EGFR
amplification (defined either by large gene clusters or >5
signals/nucleus in >50% of neoplastic cells) was detected in
seven cases (37%): three carcinomas with squamous
differentiation and four spindle cell carcinomas. One case
exhibited HER2 overexpression of grade 2+ (>10% of cells with
weak to moderate complete membrane staining), but HER2
gene amplification was not detected.
Conclusion Metaplastic breast carcinomas frequently
overexpressed EGFR, which was associated with EGFR gene
amplification in one-third of cases. Our findings suggest that
some patients with metaplastic breast carcinomas might benefit
from novel therapies targeting EGFR. Because most
metaplastic breast carcinomas overexpress EGFR without gene
amplification, further studies to evaluate EGFR activating
mutations are warranted.
CISH = chromogenic in situ hybridization; DFS = disease-free survival; EGFR = epidermal growth factor receptor; HER = human epidermal growth 
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Introduction
In recent years, the family of epidermal growth factor receptors
(EGFRs) or ERBB receptors has attracted great attention in
the literature [1]. This family includes four tyrosine kinase
receptors: EGFR (HER1/c-erbB1), human epidermal growth
factor receptor (HER)2/neu (c-erbB2), HER3 (c-erbB3) and
HER4(c-erbB4). All members of this family are characterized
by an extracellular ligand-binding region, a single membrane
spanning region, and a cytoplasmic tyrosine kinase containing
domain [1]. Although expression of the four members of the
ERBB family has been studied in several types of human
tumours [1], only EGFR and HER2 have been proven to play
major roles in different histological types of breast cancer [1-
12]. Thus far, only these two receptors have successfully been
targeted as therapy for lung [13-17] and breast cancer
[18,19].
EGFR was the first tyrosine kinase receptor to be directly
linked with human cancer. The EGFR gene maps to 7p11.2-
p2 and encodes a 170 kDa transmembrane protein [1]. EGFR
gene amplification has been described in oligodendrogliomas
[20], glioblastomas [21], lung carcinomas [13,14,22], gastric
carcinomas [23] and, recently, breast carcinomas [8,24,25].
The HER2 gene maps to chromosome 17q21 and encodes a
185 kDa glycoprotein. It is reported to be amplified and over-
expressed in several types of human tumours, including about
30% of all breast carcinomas [1,18,19]. Most importantly, in
recent years EGFR tyrosine kinase inhibitors and humanized
monoclonal antibodies against HER2 have received US Food
and Drug Administration approval and are currently being
tested in patients with lung and breast cancer.
Data on the response of patients with lung cancer have dem-
onstrated that approximately 10–15% of patients with EGFR-
positive lung carcinomas have a dramatic response to EGFR
tyrosine kinase inhibitors [15-17,22]. Interestingly, response
was linked to the presence of an activating somatic mutation
targeting the tyrosine domain of EGFR [15-17]. In addition,
Cappuzzo and coworkers [22] demonstrated that EGFR
amplification is a strong predictor of response to EGFR tyro-
sine kinase inhibitors. Unlike EGFR activating mutations,
EGFR amplifications also exhibited a statistically significant
association with survival [22].
Although HER2 gene amplification and protein overexpression
have been extensively studied in breast cancer, data on EGFR
amplification in breast cancer are limited. HER2 overexpres-
sion has been identified in 87% and 27% breast carcinomas
with EGFR overexpression [7] and gene amplification [8],
respectively. Interestingly, EGFR and HER2 coexpression in
breast cancer was recently associated with reduced overall
survival (OS) and disease-free survival (DFS) [7].
Our group and others have demonstrated that 'basal-like'
breast carcinomas and metaplastic breast carcinomas
(MBCs) consistently overexpress EGFR but usually lack
HER2 overexpression [12,26]. However, the presence of
EGFR gene amplifications have not been systematically ana-
lyzed in a series of MBCs. The aims of the present study were
threefold: to analyze the presence of EGFR gene amplifica-
tions in MBCs; to correlate the presence of EGFR amplifica-
tions with EGFR immunohistochemical overexpression; and to
assess HER2 overexpression in MBCs.
Materials and methods
Metaplastic breast carcinoma samples
Cases of MBC were identified and samples retrieved from the
pathology files of the Royal Marsden Hospital (London, UK),
the Institute of Molecular Pathology and Immunology, Univer-
sity of Porto (Porto, Portugal), and the Norwegian Radium
Hospital (Montebello, Norway). The project was approved by
the local ethics committees.
Cases of MBC were identified from the Royal Marsden from
January 1980 to March 2004 by searching the electronic Hos-
pital Information System for cases diagnosed as adenosqua-
mous carcinoma, carcinosarcoma, metaplastic breast
carcinoma, sarcomatoid carcinoma, spindle cell carcinoma
and squamous cell carcinoma, as well as from the consultation
files of one of the authors (SRL). Cases from the Institute of
Molecular Pathology and Immunology and the Norwegian
Radium Hospital were identified from the consultation files of
two of the authors (JMN and FCS, respectively). All cases
were initially reviewed by the contributing authors, who evalu-
ated additional immunohistochemical markers to corroborate
the diagnosis.
The cases were centrally reviewed by three of the authors
(JSR-F, FM and FCS) on a multiheaded microscope and clas-
sified according to previously described criteria [27-33].
Briefly, tumours were classified as matrix producing breast
carcinomas if chondroid and/or osseous matrix was observed
in the absence of spindle and osteoclast giant cell compo-
nents [31]. Neoplasms were classified as spindle cell carcino-
mas if intraductal or infiltrating ductal or squamous carcinoma
of ductal origin was contiguous or subtly merged with a spin-
dle cell proliferation of neoplastic cells, which comprised at
least 50% of the tumour bulk [30]. Carcinomas with heterolo-
gous elements were defined as tumours with an intraductal or
invasive carcinomatous component intimately admixed or sub-
tly merging with a sarcomatous spindle cell component with
evidence of chondroid, osseous, or rhabdomyoid differentia-
tion [29,32]. Carcinomas with squamous differentiation were
predominantly (>50%) or completely composed of apparent
squamous cell components admixed with areas of invasive
ductal and/or spindle cell carcinoma, in the absence of
involvement of the ovevrlying skin [28,33]. A median of two
representative blocks from each case was selected for immu-
nohistochemical and chromogenic in situ hybridization (CISH)
analysis.Available online http://breast-cancer-research.com/content/7/6/R1028
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Immunohistochemical and chromogenic in situ 
hybridization analysis
Immunohistochemistry was performed with antibodies raised
against HER2 (Herceptest®(Dako, Glosatrup, Denmark), pol-
yclonal, 1/10 epitope retrieval solution (Dako) at 98°C, predi-
luted; and CB11 (Novocastra, Newcastle-upon-Tyne, UK), 2
min in a pressure cooker, 1:100) and EGFR (31G7, 1:50,
Zymed (South San Francisco, CA, USA)), as previously
described [34]. For Her2/neu and EGFR, the Herceptest®
scoring system was applied: negative = no membrane staining
or <10% of cells stained; 1+ = incomplete membrane staining
in >10% of cells; 2+ = >10% of cells with weak to moderate
complete membrane staining; and 3+ = strong and complete
membrane staining in >10% of cells.
CISH was performed using Spot-Light amplification probes
for EGFR (Zymed) and HER2 (Zymed), in accordance with the
manufacturer protocol and as previously described [34].
Because the interpretation guidelines for Spot-Light EGFR
and  HER2 amplification probes have previously been vali-
dated [8,34,35], we did not use α-satellite probes for chromo-
somes 7 and 17, respectively. All cases were subjected to
CISH for EGFR, and only those with HER2 grade 2+ or 3+
positivity were subjected to CISH for HER2[36]. Appropriate
gene amplified breast tumour controls were included in each
run. Each section was analyzed by two of the authors (FM and
SC) on a multiheaded microscope. Only unequivocal signals
were counted. Signals were evaluated at 400× and 630×, and
at least 60 cells were evaluated for the presence of the EGFR
probe. A given tumour was considered to be amplified for
EGFR or HER2 when more than 50% of the neoplastic cells
Table 1
Summary of histological, immunohistochemical and chromogenic in situ hybridization findings
Case Histological type HER2 (Herceptest®) HER2 (CB11) EGFR (IHC) EGFR (CISH)
1 Carcinoma with squamous metaplasia - - 3+ No amp
2 Carcinoma with squamous metaplasia - - 3+ No amp
3 Carcinoma with squamous metaplasia - - 3+ No amp
4 Carcinoma with squamous metaplasia - - 3+ No amp
5 Carcinoma with squamous metaplasia - - 3+ Amp
6 Carcinoma with squamous metaplasia - - 3+ Amp
7 Carcinoma with squamous metaplasia 1+ - 3+ No amp
8 Carcinoma with squamous metaplasia - - 3+ Amp
9 Carcinoma with squamous metaplasia - - 1+ No amp
10 Spindle cell carcinoma - - 3+ No amp
11 Spindle cell carcinoma - - 3+ No amp
12 Spindle cell carcinoma - - 1+ No amp
13 Spindle cell carcinoma - - 3+ Amp
14 Spindle cell carcinoma - - - No amp
15 Spindle cell carcinoma - - 3+ Amp
16 Spindle cell carcinoma - - - No amp
17 Spindle cell carcinoma - - 3+ Amp
18 Spindle cell carcinoma - - 3+ No amp
19 Spindle cell carcinoma 2+a 1+a 3+ Amp
20 Carcinoma with heterologous elements - - 3+ No amp
21 Carcinoma with heterologous elements - - 3+ No amp
22 Matrix producing carcinoma - - 1+ No amp
23 Matrix producing carcinoma - - - No amp
24 Matrix producing carcinoma - - 3+ No amp
25 Matrix producing carcinoma - - 3+ No amp
aNo HER2 gene amplification was detected by CISH. Amp, amplification; CISH, chromogenic in situ hybridization; EGFR, epidermal growth 
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exhibited more than five signals per nuclei or large gene signal
clusters [8,34,36].
Out of the 112 cases of metaplastic breast carcinomas in our
series, 25 had sufficient material in the blocks and were suc-
cessfully analyzed by both immunohistochemistry and CISH
for EGFR and HER2.
Correlation between EGFR overexpression and 
amplification and clinicopathological parameters and 
survival
Follow-up information was available for 23 out of 25 patients,
with follow-up periods ranging from 5.5 to 124.3 months
(median 34.6 months, mean 51.9 months). The Statview soft-
ware package was used for all calculations. Correlations
between categorical variables were performed using the χ2
test and Fisher's exact test. Correlations between continuous
and categorical variables were performed with analysis of var-
iance. DFS and OS were expressed as the number of months
from diagnosis to the occurrence of an event (local recur-
rence/metastasis and disease-related death, respectively).
Cumulative survival probabilities were calculated using the
Kaplan–Meier method. Differences between survival rates
were tested using the log-rank test. All tests were two-tailed,
with a confidence interval of 95%.
Results
Table 1 summarizes the results of the histological, immunohis-
tochemical and CISH analyses. Briefly, 19 out of 25 (76%)
cases exhibited EGFR positivity of grade 3+. No samples
showed EGFR grade 2+ positivity, whereas four cases were
EGFR 1+. Out of the 19 cases with EGFR grade 3+ expres-
sion, seven (37%) exhibited EGFR gene amplification (Fig. 1).
Three out of nine carcinomas with squamous metaplasia and
four out of 10 spindle cell carcinomas had EGFR amplification,
whereas no matrix producing breast carcinomas showed any
amplification. Interestingly, similar numbers of EGFR signals
were observed in the epithelial and in the metaplastic ele-
ments. One case exhibited HER2 grade 2+ positivity with Her-
ceptest®, but HER2 gene amplification was not observed (Fig.
2).
No association between EGFR overexpression or amplifica-
tion and clinicopathological features was observed (Table 2).
EGFR overexpression showed no association with DFS or
OS. Patients with tumours harbouring EGFR amplification had
a trend toward shorter DFS and OS (Fig. 3).
Discussion
In recent studies, we and others demonstrated that MBCs fre-
quently overexpress EGFR and lack HER2 overexpression. In
a previous study [26] we demonstrated that up to 83% of all
MBCs show EGFR overexpression. Leibl and Moinfar [12]
described positivity for EGFR in 70% of MBCs, but those
authors also considered cases with grade 1+ expression to be
positive. When only grade 2+ and 3+ expression was consid-
ered to represent positivity, 60% (12/20) were positive. In the
present study we demonstrated that 76% (19/25) of MBCs
overexpressed EGFR. The differences between our findings
and those of Leibl and Moinfar [12] may be related to the dif-
ferent antibody clones used and different antigen retrieval
methods.
The mechanism underlying EGFR overexpression has not
been investigated in MBCs. In the present study we demon-
strated that EGFR is amplified in 28% (7/25) of MBCs and in
37% (7/19) of MBCs with EGFR overexpression. Although
only six cases with heterologous elements (four matrix produc-
ing carcinomas and two carcinomas with heterologous ele-
ments) were analyxed, no amplification was found in these two
subtypes of MBC. Identification of areas of squamous differen-
tiation in spindle cell carcinomas and the presence of spindle
Figure 1
EGFR overexpression and gene amplification in MBCs EGFR overexpression and gene amplification in MBCs. Photomicro-
graphs of (a) a spindle cell metaplastic breast carcinoma (haematoxylin 
and eosin) showing (b) grade 3+ immunohistochemical positivity for 
EGFR and (c) EGFR gene amplification (>5 signals per nucleus 
[CISH]). Inset in panel c: note the bizarre neoplastic cell with more than 
10 copies of EGFR. (d) Breast carcinoma with squamous metaplasia 
(haematoxylin and eosin) with (e) EGFR grade 3+ immunohistochemi-
cal positivity. (f) CISH demonstrating EGFR amplification (clusters of 
signals in the nuclei of neoplastic cells). Note the presence of one or 
two signals in the nuclei of stromal cells (arrowheads). CISH, chromog-
enic in situ hybridization; EGFR, epidermal growth factor receptor; 
MBC, metaplastic breast carcinoma.Available online http://breast-cancer-research.com/content/7/6/R1028
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cells in carcinomas with squamous metaplasia are not infre-
quent. In fact, in the seminal study conducted by Huvos and
coworkers [32] these two subtypes of MBCs were classified
under the heading 'group 1' MBCs. In addition, when EGFR is
overexpressed in carcinomas with heterologous elements and
matrix producing breast carcinomas, its expression appears to
be more conspicuous in epithelial components (data not
shown). In a recent study, Bhargava and coworkers [8] dem-
onstrated that 6% (11/175) of all breast carcinomas exhibit
EGFR amplification. Interestingly, one of these 11 cases was
a spindle cell metaplastic carcinoma with focal squamous dif-
ferentiation. Taken together, these findings suggest that
EGFR overexpression and/or gene amplification are likely to
play a role in carcinomas with squamous elements and spindle
cell carcinomas, but perhaps not in the other subtypes of
MBC.
Because the methods used by Bhargava and coworkers [8]
are identical to ours, a direct comparison is feasible. Taken
together, our results and those of Bhargava and coworkers
indicate that EGFR amplification is statistically more prevalent
in MBCs than in other types of breast carcinoma (10/174 non-
metaplastic breast carcinomas versus 8/26 metaplastic breast
carcinomas showed EGFR amplification; P  < 0.001 by
Fisher's exact test (two sided)).
Although EGFR amplification accounted for 37% of EGFR
overexpression in the present series, the majority of cases
Figure 2
EGFR and HER2 overexpression and gene amplification in a spindle cell carcinoma EGFR and HER2 overexpression and gene amplification in a spindle cell carcinoma. (a) Photomicrograph of a spindle cell carcinoma (haematoxylin 
and eosin). Immunohistochemical analysis revealed (b) EGFR grade 3+ positivity and (c) HER2 grade 2+ reactivity. (d) CISH demonstrating EGFR 
amplification (clusters of signals in the nuclei of neoplastic cells). Note the presence of one or two copies of EGFR in stromal cells (arrowheads). (e) 
CISH for HER2 gene: no amplification (2–3 gene copies/nucleus). CISH, chromogenic in situ hybridization; EGFR, epidermal growth factor recep-
tor; HER, human epidermal growth factor receptor; MBC, metaplastic breast carcinoma.
Table 2
Summary of the associations between clinicopathological parameters and EGFR overexpression and amplification
Parameter EGFR IHC PE G F R  CISH P
Negative Overexpression No Amplified
Age (years) 54.2 (13.3) 48.8 (13.3) >0.05 50.4 (13.7) 48.8 (12.7) >0.05
Size (cm) 4.0 (3.2) 4.4 (3.1) >0.05 3.8 (2.9) 5.9 (3.9) >0.05
Lympho-vascular invasion
No 2 9 >0.05 9 2 >0.05
Yes 2 9 7 4
Lymph node metastasis at diagnosis
No 3 11 >0.05 10 4 >0.05
Yes 1 5 4 2
CISH, chromogenic in situ hybridization; EGFR, epidermal growth factor receptor. IHC, immunohistochemistry.Breast Cancer Research    Vol 7 No 6    Reis-Filho et al.
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showed no amplification. EGFR activating mutations have
been described in lung cancer and in brain tumours, but these
mutations have proven extremely rare in other types of cancer,
including breast carcinomas [8,37]. However, Weber and
coworkers [38] recently described EGFR missense mutations
in sporadic and familial (BRCA1/BRCA2 related) breast can-
cer and demonstrated that these mutations are significantly
more frequent in the latter. Therefore, further analysis of EGFR
gene sequence in MBCs may explain the overexpression of
EGFR in those cases lacking EGFR amplification.
An alternative mechanism for EGFR expression in MBC may
be maintenance of a myoepithelial/basal phenotype. In fact,
expression of EGFR is part of the definition of 'basal-like'
tumours proposed by Nielsen and coworkers [39]. EGFR is
consistently expressed in myoepithelial cells of the breast [40].
We [26,41,42] and others [30,31,43-45] have demonstrated
that the vast majority of MBCs consistently express basal/
myoepithelial markers. Furthermore, indirect evidence from a
study using murine cell lines suggests that transformed
myoepithelial cells may give rise to tumours with sarcomatous
and carcinosarcomatous patterns, similar to those observed in
spindle cell carcinomas and carcinomas with heterologous
elements [46]. Therefore, one could speculate that overex-
pression of EGFR, without gene amplification, could simply
reflect maintenance of the basal-like/myoepithelial phenotype
of these lesions. Conversely, one cannot rule out that EGFR
gene amplification is one of the genetic mechanisms whereby
basal/myoepithelial differentiation pathways are activated in
transformed luminal epithelial cells.
Figure 3
EGFR overexpression and amplification: prognostic impact on DFS and OS EGFR overexpression and amplification: prognostic impact on DFS and OS. CISH, chromogenic in situ hybridization; DFS, disease-free survival; 
EGFR, epidermal growth factor receptor; OS, overall survival.Available online http://breast-cancer-research.com/content/7/6/R1028
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In the present series, there was no association between EGFR
overexpression and DFS or OS, whereas there was a trend
toward shorter DFS and OS in patients with tumours exhibit-
ing EGFR amplification. Based on our results, further studies
analyzing the prognostic impact of EGFR amplification in a
large cohort of MBCs are warranted.
The present study also confirms the results of previous analy-
ses demonstrating lack of HER2 overexpression in MBCs
[12,47], suggesting that humanized monoclonal antibodies
against HER2 play little or no role in the treatment of these
lesions.
Conclusion
Although initial studies suggested that only tumours harbour-
ing  EGFR mutations would be sensitive to EGFR tyrosine
kinase inhibitors, there are compelling data to suggest that
tumours harbouring EGFR amplification may also respond well
to these new agents [22]. Given that MBCs lack oestrogen
receptor, show EGFR overexpression and harbour EGFR
amplification in up to 28% of cases, and that some MBCs
have proven refractory to standard types of treatment, the use
of EGFR tyrosine kinase inhibitors may represent an alternative
therapeutic regimen for patients with MBC. Further studies
addressing the efficacy of EGFR inhibitors in this group of
breast carcinomas are warranted.
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